Japan says China will resume Japanese seafood imports it halted over Fukushima water discharge
Visitors check seafood sold at the seafood market 'Lalamew' near the Onahama fish port in Iwaki City, Fukushima Prefecture, on Oct. 19, 2023 in Iwaki, northeastern Japan. (AP Photo/Eugene Hoshiko)
TOKYO — China will resume Japanese seafood imports it banned in 2023 over worries about Japan's discharge slightly radioactive wastewater from the damaged Fukushima Daiichi nuclear power plant into the sea, a Japanese official said Friday.
China said their talks this week made 'substantial progress' but did not confirm an agreement with Japan on the issue that has been a significant political and diplomatic point of tension.
Agriculture Minister Shinjiro Koizumi said the agreement was reached after Japanese and Chinese officials met in Beijing and the imports will resume once paperwork is complete.
'Seafood is an important export item for Japan and a resumption of its export to China is a major milestone," Koizumi said.
Foreign Minister Takeshi Iwaya also welcomed the move, saying, 'It will be a big first step that would help Japan and China to tackle a number of remaining issues between the two countries,' such as disputes over territory, trade and wartime history.
But officials said China's ban on farm and fisheries products from 10 Japanese prefectures including Fukushima is still in place and that they will keep pushing toward their lifting.
China's General Administration of Customs, in a statement issued Friday, said the two sides on Wednesday held 'a new round of technical exchanges on the safety issues of Japanese aquatic products ... and achieved substantial progress' but did not mention an agreement.
How the disagreement over seafood imports began
China blocked imports of Japanese seafood because it said the release of the treated and diluted but still slightly radioactive wastewater would endanger the fishing industry and coastal communities in eastern China.
Japanese officials have said the wastewater will be safer than international standards and its environmental impact will be negligible. They say the wastewater must be released to make room for the nuclear plant's decommissioning and to prevent accidental leaks.
Tokyo and Beijing since March held three rounds of talks on the issue before reaching the agreement on Wednesday on the 'technical requirements' necessary for Japanese seafood exports to China to restart, Japan's Foreign Ministry said in a statement. It did not say how long it may take before the actual resumption.
Mainland China used to be the biggest overseas market for Japanese seafood, accounting for more than one-fifth of its seafood exports, followed by Hong Kong. The ban became a major blow to the fisheries industry, though the impact on overall trade was limited because seafood exports are a fraction of Japan's total exports.
Japan's government set up an emergency relief fund for Japanese exporters, especially scallop growers, and has sought alternative overseas markets.
Tokyo Electric Power Company Holdings, which operates the Fukushima Daiichi plant, has said it would compensate Japanese business owners appropriately for damages from export bans.
Why the wastewater is being treated and released into the sea
The nuclear plant had meltdowns in three reactors after being heavily damaged in the 2011 earthquake and tsunami that struck northeastern Japan. Water used to cool the reactor cores has been accumulating ever since, and officials say the massive stockpile is hampering the cleanup of the site.
The wastewater was treated and heavily diluted with seawater to reduce the radioactivity as much as possible before Japan began releasing it into the sea in August 2023.
Last September, then-Prime Minster Fumio Kishida said the two sides reached 'a certain level of mutual understanding' that China would start working toward easing the import ban and join the International Atomic Energy Agency's expanded monitoring of wastewater discharges.
People inside and outside Japan protested the initial wastewater release. Japanese fishing groups said they feared it would further damage the reputation of their seafood. Groups in China and South Korea also raised concerns.
Mari Yamaguchi, The Associated Press
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
2 hours ago
- CTV News
South Korea is voting for a new president after six months of political chaos. Here's what to know
After half a year of political turmoil, uncertainty and division, South Korea will vote for a new president to succeed Yoon Suk Yeol, the disgraced former leader who plunged the democratic nation into chaos by declaring martial law in December. This election feels particularly significant; the country, a U.S. ally and Asian economic and cultural powerhouse, has floundered for months with a revolving door of interim leaders while navigating Yoon's impeachment trial and a multipronged investigation into the fateful night of his short-lived power grab. All the while, South Korea's economy has suffered, with U.S. President Donald Trump's trade war and a potential global recession looming in the background. Two men are each promising to help the country recover if elected – a lawyer turned politician dogged by legal cases who survived an assassination attempt, and a former anti-establishment activist turned conservative minister. Polls open on Tuesday morning and a winner could be declared by Wednesday. Here's what you need to know. Who are the main candidates? The frontrunner is Lee Jae-myung, 60, of the liberal opposition Democratic Party. A former underage factory worker from a poor family, Lee became a human rights lawyer before entering politics. He is a former mayor and governor, and most recently served as a lawmaker after narrowly losing to Yoon in the 2022 presidential election. He survived an assassination attempt in January 2024 when a man stabbed him in the neck during a public event. He again made headlines on December 3, 2024 – the night Yoon declared martial law and sent troops to parliament. Lee was among the lawmakers who rushed to the legislature and pushed past soldiers to hold an emergency vote to lift martial law. He live streamed himself jumping over a fence to enter the building, in a viral video viewed tens of millions of times. On the campaign trail, Lee promised political and economic reforms, including more controls on a president's ability to declare martial law, and revising the constitution to allow two four-year presidential terms instead of the current single five-year term. He has emphasized easing tensions on the Korean Peninsula while holding on to the longtime goal of denuclearizing North Korea; he also supports boosting small businesses and growing the AI industry. But Lee has also been dogged by legal cases, including several ongoing trials for alleged bribery and charges related to a property development scandal. Separately, he was convicted of violating election law in another ongoing case that has been sent to an appeals court. Lee denies all the charges against him. Speaking to CNN in December, he claimed he had been indicted on various charges 'without any evidence or basis,' and that the allegations are politically motivated. Lee's main rival is Kim Moon-soo of the conservative People Power Party (PPP). When Yoon left the party in May, he urged supporters to back Kim – a 73-year-old former labor minister, who had been a prominent labor activist at university, even being expelled and imprisoned for his protests. He eventually joined a conservative party, and stepped into the nomination after several rounds of party infighting. The PPP initially selected Kim as its candidate; then dropped him, eyeing former Prime Minister Han Duck-soo instead. The party finally chose Kim after he filed legal challenges. But the PPP remains deeply divided and its candidate trailed Lee in pre-election polling. In a statement after his nomination, Kim vowed to seek unity and build a 'big tent' coalition to take on Lee, according to Reuters. Kim has also promised to reform the country's politics, judiciary and election management systems to rebuild public trust. His campaign emphasized making South Korea business-friendly through tax cuts and eased restrictions, and by promoting new technologies and nuclear energy. Several third-party and independent candidates are also running for the presidency. They include Lee Jun-seok, a former PPP leader who founded his own conservative New Reform Party last year. What are the issues on the table? At the forefront of voters' minds is the country's flailing economy and rising cost of living. Youth unemployment has surged and consumption has declined, with the economy unexpectedly contracting in the first quarter of this year. Part of that is due to Trump's trade war – which has hit South Korea's export-reliant economy hard. South Korea's exports to the U.S. fell sharply in the first few weeks of April after U.S. tariffs kicked in, and the nation's largest airline has warned the downturn could cost it up to $100 million a year. Though officials from both nations have met for tariff talks, the political turmoil at home is likely slowing progress and hampering a possible trade deal until a new South Korean president is elected. That's why both main candidates have focused on the economy, promising to stabilize the cost of goods and improve opportunities in housing, education and jobs. But there's a host of other problems the next president will have to tackle, too – such as the country's rapidly aging society and plummeting birth rates, which represent an urgent demographic crisis also seen in other countries in the region like Japan and China. Among the common complaints of young couples and singles are the high cost of childcare, gender inequality and discrimination against working parents. Then there are regional tensions. There's the ever-present threat from North Korea, which has rapidly modernized its armed forces, developing new weapons and testing intercontinental ballistic missiles that can reach almost anywhere in the United States. Experts have warned in recent years that the country may also be preparing to resume nuclear tests, which it paused in 2018. Across the Yellow Sea lies China, which South Korea has a strong trade relationship with – but historically fraught diplomatic relations. South Korea also maintains a close security alliance with the US, and hosts nearly 30,000 American troops in the country. In recent years, South Korea, Japan and the U.S. have drawn closer together, working to counter Chinese influence in the strategically important Asia-Pacific region. What happened to Yoon? Yoon was removed from office in April following months of legal wrangling, after parliament voted to impeach him late last year. It was a remarkable fall from grace for the former prosecutor turned politician, who rose to prominence for his role in the impeachment of another president – only to eventually meet the same fate. Soon after, Yoon moved out from the presidential residency and into an apartment in the capital Seoul. But his legal battles are ongoing; he faces charges including insurrection, an offense punishable by life imprisonment or death (though South Korea has not executed anyone in decades). Yoon denies all charges against him. Article written by Jessie Yeung, CNN
National Post
4 hours ago
- National Post
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
Article content Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes No serious adverse events considered related to rusfertide were reported Rusfertide has received Orphan Drug designation and Fast Track designation from the U.S. FDA Article content Article content NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass. — Protagonist Therapeutics, Inc. ('Protagonist') ( NASDAQ:PTGX) and Takeda ( TSE:4502/NYSE:TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. The data will be presented as a late-breaking oral presentation at the 61 st American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session (LBA3) at 2:09 pm CDT today. Article content PV is characterized by overproduction of red blood cells (erythrocytosis), which may increase blood viscosity, or thickness, potentially resulting in life threatening thrombotic events such as stroke, deep vein thrombosis and pulmonary embolism. People with PV can experience burdensome symptoms, including severe fatigue, difficulty in concentrating, night sweats and pruritus, which may negatively impact their daily functioning and quality of life. Hematocrit is the ratio of red blood cells to total amount of blood in the body. Achieving and maintaining controlled hematocrit levels of <45% is the primary treatment goal in PV to prevent thrombotic events and alleviate symptoms, but many patients still experience uncontrolled hematocrit levels with current standard of care treatments. Article content Rusfertide, an investigational, first-in-class hepcidin mimetic peptide therapeutic, is under evaluation in the Phase 3 VERIFY study for its potential to regulate iron homeostasis and red blood cell production to control hematocrit levels in patients with PV. In the study, patients dependent on frequent phlebotomy, with or without treatment with cytoreductive therapy, were randomized to receive once-weekly rusfertide or placebo, as an add-on to current standard of care treatment. Article content 'PV poses significant challenges for patients, including debilitating symptoms and the risk of serious thrombotic events, and hematocrit control is crucial to improving patient outcomes. The VERIFY study demonstrated that treatment with rusfertide controls hematocrit levels in phlebotomy-dependent patients, including patients receiving cytoreductive therapies,' said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. 'These results suggest rusfertide has the potential to become part of the standard of care treatment for patients with PV.' Article content The study met its primary endpoint, which was the proportion of patients achieving a clinical response, defined as the absence of phlebotomy eligibility during study Weeks 20-32. Study results demonstrated 76.9% of patients treated with rusfertide plus current standard of care achieved a clinical response, compared to 32.9% in the placebo plus current standard of care group (p<0.0001). 1 The response observed in the rusfertide arm was consistent across subgroups, regardless of risk status or type of concurrent cytoreductive therapy. 1 In addition, all key secondary endpoints met statistical significance in favor of the rusfertide arm compared to the placebo arm in the VERIFY study, as follows: Article content The mean number of phlebotomies was 0.5 phlebotomies per patient for those treated with rusfertide plus current standard of care compared to 1.8 phlebotomies per patient for those treated with placebo plus current standard of care during Weeks 0-32 (p<0.0001). 1 Only 27% of patients treated with rusfertide plus current standard of care required phlebotomy between Weeks 0-32, compared to 78% of patients who received placebo plus current standard of care. The mean number of phlebotomies during Weeks 0-32 in the rusfertide arm was reduced across subgroups, including risk status and use of concurrent cytoreductive therapy, versus the placebo arm. 62.6% of patients treated with rusfertide plus current standard of care maintained hematocrit levels below 45% versus 14.4% treated with placebo plus current standard of care (p<0.0001). 1 Rusfertide also showed statistically significant improvements in mean change from baseline to Week 32 in PROMIS Fatigue 2 (p<0.03) and the MFSAF Total Symptom Score 3 (p<0.03). Rusfertide is the first investigational therapy to prospectively demonstrate a statistically significant improvement in these patient-reported outcomes (PROs) of fatigue and symptom burden in patients with PV. 1 Article content Rusfertide was generally well tolerated. The majority of adverse events were low grade and non-serious and no serious adverse events considered related to rusfertide were reported. There was no evidence of increased risk of cancer in patients treated with rusfertide plus current standard of care compared to patients treated with placebo plus current standard of care at the time of the primary analysis. Cancer events were reported in one patient in the rusfertide arm (0.7%) and in seven patients in the placebo arm (4.8%). The most common treatment-emergent adverse events were localized injection site reactions (55.9%), anemia (15.9%) and fatigue (15.2%). 1 Article content 'These findings underscore rusfertide's potential as a first-in-class erythrocytosis-specific treatment for PV and validate more than a decade of scientific innovation originating from Protagonist's peptide technology platform,' said Dinesh V. Patel, Ph.D., President and Chief Executive Officer at Protagonist. 'We would like to thank all the patients, study staff and investigators for participating in the VERIFY study. We are pleased to partner with Takeda as we continue to advance rusfertide to potentially transform the standard of care in PV patients around the world.' Article content 'These promising pivotal data strongly support rusfertide's potential benefit for a broad spectrum of patients with PV who may be receiving current standard of care therapies but not achieving adequate hematocrit control,' said Phuong Khanh (P.K.) Morrow, M.D., Head of the Oncology Therapeutic Area Unit (OTAU) at Takeda. 'We look forward to receiving additional data from the VERIFY trial later this year, advancing rusfertide towards regulatory approval and continuing our collaboration with Protagonist to bring this innovative therapy to patients.' Article content Rusfertide has received Orphan Drug designation and Fast Track designation from the U.S. Food & Drug Administration (FDA). Article content Takeda will host an investor call regarding this update on Article content An on-demand replay will be made available on Takeda's website after the conclusion of the event. Article content The dial-in numbers for Protagonist's investor update on Monday, June 2nd at 5:00-6:00 am PDT/ 8:00-9:00 am EDT are: Article content US-based Investors: 1-877-300-8521 International Investors: 1-412-317-6026 Conference Call ID: 10199589 Article content The webcast link for the event can be found here: Article content A replay of the presentation will be available on the Protagonist Investor Relations Events and Presentations webpage following the event. Article content About VERIFY Article content The Phase 3 VERIFY study (NCT05210790) is an ongoing, three-part, global, randomized, placebo-controlled study evaluating rusfertide in 293 patients with polycythemia vera over a 156-week period. The study is evaluating the efficacy and safety of once-weekly, subcutaneously self-administered rusfertide in patients with uncontrolled hematocrit who are phlebotomy-dependent despite current standard of care treatment, which could include hydroxyurea, interferon and/or ruxolitinib. The primary endpoint of the study was the proportion of patients achieving a response during Weeks 20-32, which was defined as the absence of 'phlebotomy eligibility.' To meet phlebotomy eligibility, patients in the study were required to have: confirmed hematocrit ≥45% that was ≥3% higher than their baseline hematocrit value, or hematocrit ≥48%. Article content All patients have completed their participation in the randomized, placebo-controlled portion of the study evaluating the efficacy and safety of rusfertide plus current standard of care versus placebo plus current standard of care and are now in the open-label portions of the study. Article content About Protagonist Article content Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA expected in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ('IL-23R') which is licensed to JNJ Innovative Medicines ('JNJ'), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program. Article content Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit Article content This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of rusfertide and the timing of rusfertide regulatory submissions. In some cases, you can identify these statements by forward – looking words such as 'anticipate,' 'believe,' 'may,' 'will,' 'expect,' or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading 'Risk Factors' contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. Article content Takeda Important Notice Article content For the purposes of this notice, 'press release' means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ('Takeda') regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. Article content The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, 'Takeda' is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words 'we', 'us' and 'our' are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Article content This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as 'targets', 'plans', 'believes', 'hopes', 'continues', 'expects', 'aims', 'intends', 'ensures', 'will', 'may', 'should', 'would', 'could', 'anticipates', 'estimates', 'projects', 'forecasts', 'outlook' or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: or at Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results. Article content This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. Article content Kuykendall A et al. Results From VERIFY, a Phase 3, Double-Blind, Placebo (PBO)-Controlled Study of Rusfertide for Treatment of Polycythemia Vera (PV). Oral presentation at: American Society of Clinical Oncology (ASCO) Annual Meeting, June 1, 2025. Chicago, IL. LBA3. PROMIS Fatigue Short Form 8a Total T-Score. MFSAF v4.0 Total Symptom Score 7. Article content Article content Article content Contacts Article content Protagonist Investor Relations Contact Corey Davis, Ph.D. LifeSci Advisors +1 212 915 2577 cdavis@ Article content Protagonist Media Contact Virginia Amann, Founder/CEO ENTENTE Network of Companies +1 833 500 0061 ext 1 virginiaamann@ Article content Article content
CTV News
15 hours ago
- CTV News
North Korea deploys mystery balloon-like objects to stricken warship, satellite photos show
A satellite image shows what appear to be white balloons floating above the stranded North Korean warship that was damaged after a failed launch, in Chongjin, North Korea, on May 24. Maxar Technologies via CNN Newsource SEOUL, South Korea — New satellite images show North Korea has deployed what appear to be balloons alongside its damaged 5,000-ton warship that has been laying on its side and partially submerged since a botched launch last week. While the purpose of the objects is unclear, experts told CNN they could be used to help get the ship back upright, or protect it from the prying eyes of drones. The stricken destroyer was the country's newest warship and was meant to be a triumph of North Korea's ambitious naval modernization effort. Instead, a malfunction in the launch mechanism on May 21 caused the stern to slide prematurely into the water, crushing parts of the hull and leaving the bow stranded on the shipway, state media KCNA reported, in a rare admission of bad news. North Korean leader Kim Jong Un, who witnessed the failed launch in the northeastern city of Chongjin, called it a 'criminal act' and ordered the country to swiftly repair the as-yet-unnamed ship before the late-June plenary session of the ruling Workers' Party, calling it a matter of national honor. Officials have since scrambled to undo the damage and punish those they claim are responsible, detaining four people in recent days, including the shipyard's chief engineer. Analysts say it appears balloons are being used in North Korea's effort to swiftly repair the destroyer. 'It looks like what appear to be balloons have been installed not to refloat the ship, but to prevent the ship from further flooding,' said Rep. Yu Yong-weon, a South Korean National Assembly lawmaker and military analyst. Retired United States Navy Cpt. Carl Schuster said if the objects are indeed balloons, they could have one of two purposes – either to prevent 'low- to mid-level drone reconnaissance,' or to reduce the stress on the part of the ship still stranded on the pier. 'That is the area that is most likely to have been damaged, suffered the most severe damage and remains under intense stress while the forward area remains out of the water,' he said. Nick Childs, senior fellow for naval forces and maritime security at the International Institute for Strategic Studies, said North Korea could be in danger of further damaging the ship if it's using balloons to keep it afloat or raise it. 'It is highly likely that the ship is under quite a lot of stress anyway,' and lifting from above could compound those stresses, he said. Normal procedure would be to get as much buoyancy as possible in the ship and then raise it from below, Childs said. According to satellite images shared by Maxar Technologies, more than a dozen white, balloon-like objects have been deployed around the destroyer since May 23. Based on the objects' shape and what appear to be tail fins, they could be smaller versions of what are known as aerostat aircraft, balloons with a slight resemblance to dirigibles, defense experts told CNN. Like blimps, dirigibles get buoyancy from a lifting gas that allows them to float in air or in water. The images don't appear to show any flotation bladders supporting the hull or the body of the ship, Schuster said – something the US might use in such a situation. He added that North Korea's maritime industry might not be advanced enough for such techniques. North Korean state media had previously reported that the damage was less severe than initially feared, and that there were no holes in the hull, though it was scratched along the side and some seawater had entered the stern. It estimated repairs could take about 10 days – though analysts are skeptical. Schuster had previously told CNN that repair work could take up to six months, depending on how far the hull damage extends, how much water entered the warship, and how much 'salt crust' might have formed on metal surfaces such as joints. The ship's precarious position also makes the salvage operation unusually complex. 'Having it half in and half out of the water is basically the worst possible situation,' said Decker Eveleth, an associate research analyst at CNA, a nonprofit specializing in defense research. He added that the operation would be simpler if the ship had fully capsized into the water, or if it had fallen over entirely on land. 'But as it's half on land and half on water – if you try to pull the sunken half out, you're risking twisting and breaking the keel,' Eveleth said, referring to the structural spine running along the ship's bottom. 'And if you do that, the whole ship is junk.' Childs said North Korea may have to cut the ship into pieces and then try to salvage what it can because righting it from its current position is an extremely complex task. 'Very often the only way you clear the dock … is to dismantle at least part of the ship to make the operation easier, right what you have left and tow it away and make a decision on whether you rebuild it or scrap it,' he said.
